Viking Therapeutics Inc
VKTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.53B
Close$
$1.47
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.53 Billion |
|---|---|
| Enterprise Value | $3.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 0.68 |
| Outstanding Shares | 115,568,000 |
Return
| Return on Equity | -94.11% |
|---|---|
| Return on Assets | -77.66% |
| Return on Invested Capital | -100.02% |
Valuation & Multiples
| P/E Ratio | -7.43 |
|---|---|
| PEG | -3.01 |
| Price to Sales | - |
| Price to Book Ratio | 9.47 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.79 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 29, 2026
EPS Estimate
$-1.01
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 29, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3185▼ 12.17% |
|---|---|
| Total Calls | 6,208,934▼ 22.86% |
| Total Puts | 1,977,600▼ 44.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.20%▲ 0.16% |
|---|---|
| Total Invested | $2.43B▼ 17.27% |
| Investors Holding | 438▼ 23.00% |
ESG Score
No data
About Viking Therapeutics Inc
CEO: Brian Lian